Repurposed drug may be first targeted treatment for serious kidney disease

Date:

November 8, 2013

Source:

Massachusetts General Hospital

Summary:

A team of researchers is reporting that treatment with abatacept appeared to halt the course of focal segmental glomerulosclerosis in five patients, preventing four from losing transplanted kidneys and achieving disease remission in the fifth.

Share:

Total shares:

FULL STORY

A drug approved for the treatment of rheumatoid arthritis may also turn out to be the first targeted therapy for one of the most common forms of kidney disease, a condition that almost inevitably leads to kidney failure. A team led by Massachusetts General Hospital (MGH) researchers is reporting that treatment with abatacept (Orencia) appeared to halt the course of focal segmental glomerulosclerosis (FSGS) in five patients, preventing four from losing transplanted kidneys and achieving disease remission in the fifth. The report is being issued online in the New England Journal of Medicine to coincide with a presentation at the American Society for Nephrology annual meeting.

"We identified abatacept as the first personalized, targeted treatment for kidney disease and specifically for FSGS, a devastating and largely untreatable disease," says Peter Mundel, MD, of the Division of Nephrology in the MGH Department of Medicine, senior author of the NEJM paper. "We also identified a biomarker that helps us discern which patients are most likely to benefit from therapy with abatacept."

FSGS is characterized by the formation of scar tissue in the glomeruli, the kidney's essential filtering units. Some forms of FSGS are inherited and some have no known cause, but the vast majority of cases develop in individuals with hypertension, obesity or diabetes. Although the underlying mechanism is unclear, FSGS disrupts the function of podocytes, cells within the glomeruli that are crucial to kidney function. While treatment with steroids and some immunosuppressive drugs helps some patients, the drugs' side effects make long-term use problematic.

Previous research by Mundel's team found that the expression on podocytes of an immune molecule called B7-1 signaled the breakdown of the kidney's filtering function, leading to protein leakage into the urine (proteinuria) and ultimate kidney failure. Currently approved for the treatment of rheumatoid arthritis and being studied for other conditions, abatacept inhibits the activity of B7-1, a molecule that is not expressed in healthy podocytes. After in vitro tests indicated that abatacept blocked the primary pathogenic effect of B7-1 expression in podocytes, the team tested treatment with the drug in five FSGS patients -- four with recurrent disease affecting a transplanted kidney and one with treatment-resistant disease who was at high risk for kidney failure.

In all five patients, abatacept treatment induced remission of FSGS-caused proteinuria. Two of those with recurrent disease have remained in remission with a single dose of abatacept for three and four years. The other two required a second dose when proteinuria reappeared a few weeks later and have been in remission for 10 and 12 months respectively. The patient with high-risk, treatment-resistant disease, who is being treated at MGH, went into remission for the first time in more than a year, continues in remission a year later and has resumed a normal lifestyle. While she continues to receive monthly doses of abatacept, she no longer needs the high-dose steroids and immunosuppressive drugs she had been dependent on, some of which actually increase the risk for kidney failure.

An associate professor of Medicine at Harvard Medical School, Mundel explains that, while a large-scale clinical trial is needed, he and his colleagues are hopeful that abatacept will prove an effective treatment for kidney disease characterized by B7-1 expression on podocytes. "We have a decade of good experience with the use of abatacept for rheumatoid arthritis, so we have every reason to believe that it will be an excellent long-term option for the treatment of all B7-1-positive diseases, including FSGS and perhaps diabetic kidney disease."

Massachusetts General Hospital. "Repurposed drug may be first targeted treatment for serious kidney disease." ScienceDaily. ScienceDaily, 8 November 2013. <www.sciencedaily.com/releases/2013/11/131108153524.htm>.

Massachusetts General Hospital. (2013, November 8). Repurposed drug may be first targeted treatment for serious kidney disease. ScienceDaily. Retrieved August 2, 2015 from www.sciencedaily.com/releases/2013/11/131108153524.htm

Massachusetts General Hospital. "Repurposed drug may be first targeted treatment for serious kidney disease." ScienceDaily. www.sciencedaily.com/releases/2013/11/131108153524.htm (accessed August 2, 2015).

July 31, 2015  School is just around the corner, which means backpacks and packed lunches await your children. One expert offers tips for parents to promote healthy dental habits while away from ... read more

July 29, 2015  By blocking the expression of a certain gene in patients, researchers have contributed to the demonstration of great decreases in the concentration of triglycerides in their ... read more

July 29, 2015  Viewing aquarium displays led to noticeable reductions in blood pressure and heart rate, a research team found in the first study of its kind. They also noted that higher numbers of fish helped to ... read more

Nov. 13, 2014  Transplanted kidneys may not function long-term if they come from donors with variants in a particular gene. Results from a study confirmed that 2 APOL1 gene variants in donor kidneys were associated ... read more

Mar. 27, 2014  A receptor called B7-1 is expressed by kidney cells during the progression of kidney disease in diabetic mice and humans. Targeting this receptor with an available drug called CTLA4-Ig, or abatacept, ... read more

Nov. 8, 2012  Patients with a disease that is a leading cause of kidney failure tend to have high levels of a particular factor circulating in their blood, according to a study. The findings suggest that the ... read more

Oct. 24, 2011  African-Americans with two copies of the APOL1 gene have about a four percent lifetime risk of developing a form of kidney disease, according to scientists. The finding brings scientists closer to ... read more